Bial-Portela Ca & S.a.

Other

Bial-Portela & Cª, S.a.

Jorge Bruno Reis Wahnon

William Maton

Domenico Russo

David Alexander Learmonth

Laszlo Erno Kiss

Patricio Manuel Vieira Araujo Soares Da Silva

Tibor Eszenyi

Rita Gusmao De Noronha

Carla Patricia Da Costa Pereira Rosa

Alexander Beliaev

Michael Kreis

Jean-Marie Schneider

Klaus Reiter

Patrício Manuel Vieira Araújo Soares Da Silva

Jonathan Madec

Axel Zimmermann

Bjoern Schlummer

Brian Broadbelt

Carla Patrícia Da Costa Pereira Rosa

Axel Zimmerman

Klaus Rieter

Rita GUSMÃO De Noronha

The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa' with a carbamoyl halide of the formula: R1R2NC(&#x2550;O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa&#x2032; is prepared by oxidation of the derivative of R5 and R6, R6-C(&#x2550;O)CHR5 to form a glyoxal intermediate R6-C(&#x2550;O)(C&#x2550;O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa&#x2032; and wherein the compound substituents are as defined herein. 

Processes for the synthesis of substituted urea compounds

A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

Urea compounds and their use as enzyme inhibitors

The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.

Process for preparing 1,3-dihydroimidazole-2-thione derivatives

There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor

A process for preparing a substitute urea of Formula (II) or Formula (I), or a pharmaceutically acceptable salt or ester thereof: the process comprising the reaction of a carbamate of Formula (II'): Formula (I&#x2032;): with a primary or secondary amine of the formula R1R2NH, wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.

Process for the synthesis of substituted urea compounds

Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives

Intermediate for preparing a catechol-O-methyltransferase inhibitor

Growing community of inventors

S. Mamede do Coronado, Portugal

Jorge Bruno Reis Wahnon